BioSpace News Archive

Aurora Spine Corporation announced today that it has entered into a joint co-marketing agreement with Echolight Medical, a manufacturer of the radiation-free EchoS portable densitometer used for patient assessment of bone mineral density (BMD) and the quality of bone microarchitecture independent of BMD.

Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), together with its subsidiary Palladio Biosciences, Inc. (“Palladio”), today announced it has started dosing of the first subject in its pivotal Phase 3 clinical trial (“ACTION Study”) evaluating lixivaptan as a potential treatment for Autosomal Dominant Polycystic Kidney Disease (“ADPKD”).

BridgeBio Pharma, Inc. today reported its financial results for the fourth quarter ended December 31, 2021 and provided an update on the Company’s operations.

Trevi Therapeutics, Inc. today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF).

DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) today announced that Dr. Dorothea Wenzel has been appointed to its Board of Directors (the “Board”).

Science 37 Holdings, Inc. today announced its Operating System has earned ISO 27001 certification for cybersecurity management as well as the ISO 27701:2019 privacy management certification extension.

Vericel Corporation reported financial results and business highlights for the fourth quarter and year ended December 31, 2021, and provided full-year 2022 financial guidance.

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the fourth quarter and full year of 2021 after the U.S. market close on Tuesday, March 22nd, 2022.

Achieve Life Sciences, Inc. today announced it will report its fourth quarter and year-end 2021 financial results and provide an update on the cytisinicline development program on Thursday, March 10, 2022, at 4:30 PM EST.

The global veterinary dental equipment market is anticipated to touch new heights in the near future.